CBP mediated DOT1L acetylation confers DOT1L stability and promotes cancer metastasis

Conclusions: DOT1L acetylation by CBP drives CRC progression and metastasis. Targeting DOT1L deacetylation signaling is a potential therapeutic strategy for DOT1L-driven cancers.

Source: Theranostics - July 3, 2020 Category: Molecular Biology Authors: Chaohua Liu, Qiaoyan Yang, Qian Zhu, Xiaopeng Lu, Meiting Li, Tianyun Hou, Zhiming Li, Ming Tang, Yinglu Li, Hui Wang, Yang Yang, Haiying Wang, Ying Zhao, He Wen, Xiangyu Liu, Zebin Mao, Wei-Guo Zhu Tags: Research Paper Source Type: research